Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27894417 | 0.98 | WDR5 (0.47) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL870351 | 0.95 | HDAC1 (0.45) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL871726 | 0.93 | ALDH1A1 (0.45) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14701710 | 0.84 | WDR5 (0.50) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16793684 | 0.80 | WDR5 (0.47) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11097275 | 0.79 | WDR5 (0.46) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8811741 | 0.79 | WDR5 (0.46) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4090031 | 0.79 | HDAC1 (0.50) | WDR5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18377471 | 0.78 | HDAC1 (0.50) | WDR5ALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL12443590 | 0.76 | HPGD (0.60) | WDR5ALDH1A1NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10829484-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829484-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-111867584-A | Ethylenediamine-heterocyclic derivatives as inhibitors of protein arginine methyltransferase | 德州大学系统董事会 | 2020-10-30 | — | — | CN | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3444251-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3080122-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| WO-2015089327-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN IDEC MA INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| EP-2534170-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | Pharmascience Inc. (CA) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098904-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | WO | disclosed |
| CN-101189228-A | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | PFIZER PROD INC (US) | 2008-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | WDR5 764/4885ALDH1A1 4122/4885NPC1 818/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | WDR5 1483/4885ALDH1A1 4256/4885NPC1 3802/4885 |
| US-10829484-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K11, PRKAR2B, MAP3K13 | WDR5 4026/4885ALDH1A1 4034/4885NPC1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.